Search results for "Coronary Angiography"

showing 10 items of 308 documents

Pre-operative Diagnosis of Silent Coronary Ischaemia May Reduce Post-operative Death and Myocardial Infarction and Improve Survival of Patients Under…

2019

Objective Patients undergoing peripheral vascular surgery have increased risk of death and myocardial infarction (MI), which may be due to unsuspected (silent) coronary ischaemia. The aim was to determine whether pre-operative diagnosis of silent ischaemia using coronary computed tomography (CT) derived fractional flow reserve (FFRCT) can facilitate multidisciplinary care to reduce post-operative death and MI, and improve survival. Methods This was a single centre prospective study with historic controls. Patients with no cardiac symptoms undergoing lower extremity surgical revascularisation with pre-operative coronary CTA-FFRCT testing were compared with historic controls with standard pre…

Malemedicine.medical_specialtyTime FactorsComputed Tomography Angiographymedicine.medical_treatmentMyocardial InfarctionFractional flow reserveCoronary Artery Disease030204 cardiovascular system & hematology030230 surgeryCoronary AngiographyRisk Assessment03 medical and health sciencesPeripheral Arterial Disease0302 clinical medicinePredictive Value of TestsRisk FactorsInternal medicinemedicineHumansMyocardial infarctionProspective StudiesProspective cohort studyAgedmedicine.diagnostic_testbusiness.industryCoronary StenosisPercutaneous coronary interventionVascular surgeryMiddle Agedmedicine.diseaseFractional Flow Reserve MyocardialStenosismedicine.anatomical_structureLower ExtremityCase-Control StudiesAngiographyAsymptomatic DiseasesCardiologySurgeryFemaleCardiology and Cardiovascular MedicinebusinessVascular Surgical ProceduresArteryEuropean journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery
researchProduct

Iron Metabolism Contributes to Prognosis in Coronary Artery Disease: Prognostic Value of the Soluble Transferrin Receptor Within the AtheroGene Study

2020

Background Coronary heart disease is a leading cause of mortality worldwide. Iron deficiency, a frequent comorbidity of coronary heart disease, causes an increased expression of transferrin receptor and soluble transferrin receptor levels (sTfR) levels, while iron repletion returns sTfR levels to the normal physiological range. Recently, sTfR levels were proposed as a potential new marker of iron metabolism in cardiovascular diseases. Therefore, we aimed to evaluate the prognostic value of circulating sTfR levels in a large cohort of patients with coronary heart disease. Methods and Results The disease cohort comprised 3423 subjects who had angiographically documented coronary heart diseas…

Malemedicine.medical_specialtyTime FactorsIronMyocardial InfarctionCoronary Artery Disease030204 cardiovascular system & hematologyCoronary AngiographyRisk AssessmentGastroenterologyCoronary artery disease03 medical and health sciences0302 clinical medicinePredictive Value of TestsRisk FactorsGermanyInternal medicineReceptors TransferrinmedicineHumansCoronary Heart Diseasesoluble transferrin receptorAgedOriginal Research030304 developmental biologySoluble transferrin receptorchemistry.chemical_classification0303 health sciencesbiologybusiness.industryMyocardiumMetabolismIron deficiencyMiddle AgedPrognosismedicine.diseaseComorbidityCoronary heart diseasechemistryTransferrinbiology.proteinbiomarkerBiomarker (medicine)FemaleCardiology and Cardiovascular MedicinebusinessBiomarkersJournal of the American Heart Association
researchProduct

Usefulness of the neutrophil to lymphocyte ratio in predicting long-term mortality in ST segment elevation myocardial infarction.

2007

Neutrophil to lymphocyte ratio (N/L) has been associated with poor outcomes in patients who underwent cardiac angiography. Nevertheless, its role for risk stratification in acute coronary syndromes, specifically in patients with ST-segment elevation myocardial infarction (STEMI), has not been elucidated. We sought to determine the association of N/L maximum value (N/L max) with mortality in the setting of STEMI and to compare its predictive ability with total white blood cell maximum count (WBC max). We analyzed 515 consecutive patients admitted with STEMI to a single university center. White blood cells (WBC) and differential count were measured at admission and daily for the first 96 hour…

Malemedicine.medical_specialtyTime FactorsNeutrophilsMyocardial InfarctionCoronary AngiographyElectrocardiographyLeukocyte CountWhite blood cellInternal medicineCause of DeathConfidence IntervalsST segmentMedicineHumansMyocardial infarctionLymphocytesNeutrophil to lymphocyte ratioAgedProportional Hazards ModelsRetrospective Studiesmedicine.diagnostic_testbusiness.industryProportional hazards modelST elevationMiddle Agedmedicine.diseasePrognosisSurvival Ratemedicine.anatomical_structureCardiologyFemaleMyocardial infarction diagnosisCardiology and Cardiovascular MedicinebusinessElectrocardiographyFollow-Up StudiesThe American journal of cardiology
researchProduct

9-Month Clinical and Angiographic Outcomes of the COBRA Polyzene-F NanoCoated Coronary Stent System

2016

Abstract Objectives The aim of this study was to assess the safety and effectiveness of the COBRA Polyzene-F NanoCoated Coronary Stent System (CeloNova Biosciences, San Antonio, Texas) for the treatment of de novo coronary artery lesions. Background Polyzene-F–coated coronary stents have shown reduced thrombogenicity and inflammation in preclinical studies. Methods Patients with de novo coronary artery lesions meeting eligibility criteria were enrolled in a nonrandomized, prospective clinical trial. The primary endpoint was target vessel failure (TVF) (defined as a composite of cardiac death, myocardial infarction, or clinically driven target vessel revascularization) at 9 months. A pre-spe…

Malemedicine.medical_specialtyTime FactorsPolymersmedicine.medical_treatmentCoronary Artery Disease030204 cardiovascular system & hematologyCoronary AngiographyProsthesis DesignCoronary RestenosisCoronary artery disease03 medical and health sciencesOrganophosphorus Compounds0302 clinical medicineCoated Materials BiocompatibleCoronary thrombosisRestenosisPredictive Value of TestsRisk FactorsInternal medicineAngioplastyCoronary stentmedicineClinical endpointHumansProspective Studies030212 general & internal medicineMyocardial infarctionAngioplasty Balloon CoronaryAgedbusiness.industryCoronary ThrombosisStentMiddle Agedmedicine.diseaseCoronary VesselsSurgeryTreatment OutcomeCardiologyNanoparticlesFemaleStentsCardiology and Cardiovascular MedicinebusinessJACC: Cardiovascular Interventions
researchProduct

Relation of markers of inflammation (C-reactive protein, fibrinogen, von Willebrand factor, and leukocyte count) and statin therapy to long-term mort…

2002

We evaluated a possible interaction between statins and inflammation in 1,246 patients with angiographically diagnosed coronary artery disease. Four different inflammatory markers were determined: high, sensitive C-reactive protein (hs-CRP) (p = 0.001), fibrinogen (p = 0.006), von Willebrand factor (p = 0.006), and leukocyte count (p = 0.03); these levels were significantly higher among the 88 patients who died of cardiac causes during follow-up (median 2.9 years) than among survivors. In a multivariate backward stepwise Cox regression mode, only hs-CRP was evaluated to be a significant predictor of death from coronary artery disease. This prediction was lost in statin-treated patients. Com…

Malemedicine.medical_specialtyTime FactorsStatinmedicine.drug_classCoronary Artery DiseaseCoronary AngiographyFibrinogenCoronary artery diseaseLeukocyte CountVon Willebrand factorPredictive Value of TestsRisk FactorsInternal medicinevon Willebrand FactormedicineHumansProspective StudiesRisk factorProspective cohort studyAgedProportional Hazards Modelsbiologybusiness.industryC-reactive proteinFibrinogenMiddle Agedmedicine.diseaseC-Reactive ProteinMultivariate Analysisbiology.proteinCardiologyFemaleHydroxymethylglutaryl-CoA Reductase InhibitorsCardiology and Cardiovascular MedicinebusinessAcute-Phase ProteinsFollow-Up Studiesmedicine.drugLipoproteinThe American Journal of Cardiology
researchProduct

Influence of gender on delays and early mortality in ST-segment elevation myocardial infarction: Insight from the first French Metaregistry, 2005–201…

2018

International audience; Background - Women show greater mortality after acute myocardial infarction. We decided to investigate whether gender affects delays and impacts in-hospital mortality in a large population.Methods and results - We performed a patient-level analysis of 7 French MI registries from different regions from January 2005 to December 2012. All patients with acute STEMI were included within 12 h from symptom onset and a first medical contact with a mobile intensive care unit an emergency department of a hospital with percutaneous coronary intervention facility. Primary study outcomes were STEMI, patient and system, delays. Secondary outcome was in-hospital mortality. 16,733 p…

Malemedicine.medical_specialtyTime Factorsmedicine.medical_treatment030204 cardiovascular system & hematologyCoronary AngiographyClinical researchSTEMIElectrocardiography03 medical and health sciencesSex Factors0302 clinical medicine[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemRisk FactorsGender issuesmedicineHumansST segmentRegistries030212 general & internal medicineMyocardial infarctionSex DistributionSurvival rateAgedRetrospective StudiesAged 80 and overmedicine.diagnostic_testbusiness.industryPercutaneous coronary interventionRetrospective cohort studyEmergency departmentMiddle Aged[ SDV.MHEP.CSC ] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemPrognosismedicine.disease3. Good healthSurvival RateClinical researchEmergency medicineST Elevation Myocardial InfarctionFemale[SDV.IB]Life Sciences [q-bio]/BioengineeringCardiology and Cardiovascular MedicinebusinessElectrocardiographyFollow-Up StudiesInternational Journal of Cardiology
researchProduct

Outcomes of a routine invasive strategy in elderly patients with non-ST-segment elevation myocardial infarction from 2005 to 2014: results from the P…

2019

Background Elderly patients (≥75 years old) with non-ST-segment elevation myocardial infarction (NSTEMI) represent a large subgroup of all cases. They are rarely included in randomized trials because of comorbidities and concerns about complications. Furthermore, invasive treatments are used less frequently in this patient group. The aim of this study was to analyze trends in invasive procedures and outcomes in elderly patients with NSTEMI from 2005 to 2014. Patients and methods We analyzed 68 978 elderly patients with NSTEMI enrolled in the prospective, nationwide Polish Registry of Acute Coronary Syndromes from 2005 to 2014. Results Elderly patients accounted for 34.9% of all patients wit…

Malemedicine.medical_specialtyTime Factorsmedicine.medical_treatment030204 cardiovascular system & hematologyCoronary AngiographyRisk Assessmentlaw.invention03 medical and health sciences0302 clinical medicinePercutaneous Coronary InterventionSex FactorsRandomized controlled triallawPredictive Value of TestsRisk FactorsInternal medicinemedicineST segmentHumans030212 general & internal medicineMyocardial infarctionHospital MortalityRegistriesHealthcare DisparitiesNon-ST Elevated Myocardial InfarctionAgedbusiness.industryAge FactorsPercutaneous coronary interventionGeneral MedicineMiddle Agedmedicine.diseaseConfidence intervalStandardized mortality ratioTreatment OutcomePredictive value of testsRelative riskFemalePolandCardiology and Cardiovascular MedicinebusinessCoronary artery disease
researchProduct

Safety and tolerability of abciximab in patients with acute myocardial infarction and failed thrombolysis.

2003

Abstract Aim: The aim of this study was to evaluate glycoprotein IIb/IIIa receptor inhibitor effectiveness in AMI patients with unsuccessful thrombolysis. Methods: Eighty-four patients hospitalised within 4 h of symptom onset were randomised (single blind) into two groups. Regardless of the group, placebo or GP IIb/IIIa inhibitors were administered to patients who did not present with reperfusion signs 30 min after starting thrombolysis and 30–60 min after the end of full thrombolysis in patients with pain recurrence and ST-segment elevation. Reperfusion was assessed by the creatine kinase peak occurring within 12 h, by the observation of rapid ST-segment reduction (50–70% within 1 h) in 12…

Malemedicine.medical_specialtyTime Factorsmedicine.medical_treatmentAbciximabMyocardial InfarctionMyocardial ReperfusionPlatelet Glycoprotein GPIIb-IIIa ComplexPlaceboCoronary AngiographyAnginaElectrocardiographyImmunoglobulin Fab FragmentsInternal medicineFibrinolysisAbciximabmedicineHumansSingle-Blind MethodThrombolytic TherapyMyocardial infarctionTreatment FailureAngioplasty Balloon CoronaryAspirinbusiness.industryAntibodies MonoclonalThrombolysisMiddle Agedmedicine.diseaseTolerabilityResearch DesignAnesthesiaTissue Plasminogen ActivatorCardiologyFemaleSafetyCardiology and Cardiovascular MedicinebusinessPlatelet Aggregation Inhibitorsmedicine.drugInternational journal of cardiology
researchProduct

Initial experience with the novel BioMime 60 mm-long sirolimus-eluting tapered stent system in long coronary lesions

2017

Malemedicine.medical_specialtyTime Factorsmedicine.medical_treatmentCoronary Artery Disease030204 cardiovascular system & hematologyCoronary AngiographyProsthesis Design03 medical and health sciencesPercutaneous Coronary Intervention0302 clinical medicineRisk FactorsmedicineHumansProspective Studies030212 general & internal medicineNon-ST Elevated Myocardial InfarctionAgedSirolimusbusiness.industryStentCardiovascular AgentsDrug-Eluting StentsMiddle AgedSurgeryTreatment OutcomeSirolimusFemaleCardiology and Cardiovascular Medicinebusinessmedicine.drugEuroIntervention
researchProduct

Real world safety and efficacy of the Janus Tacrolimus-Eluting stent: long-term clinical outcome and angiographic findings from the Tacrolimus-Elutin…

2009

Objectives: We sought to evaluate the safety and performance of the Janus Tacrolimus-Eluting stent (TES) in an unselected population of patients, without application of restrictive clinical or angiographic criteria. Background: Continued attention to the safety, efficacy, and deliverability of first-generation drug eluting stents has led to the development of new antiproliferative agents with alternative stent platforms and different drug carrier vehicles. Methods: The TEST (Tacrolimus Eluting STent) registry is a prospective, nonrandomized single-center registry in which 140 consecutive patients who underwent single- or multi-vessel percutaneous coronary intervention between February 2005 …

Malemedicine.medical_specialtyTime Factorsmedicine.medical_treatmentPopulationMyocardial InfarctionRestenosiKaplan-Meier EstimateCoronary AngiographyProsthesis DesignRisk AssessmentTacrolimusCoronary RestenosisRestenosismedicineHumansRadiology Nuclear Medicine and imagingMyocardial infarctionProspective StudiesRegistriesAngioplasty Balloon CoronaryeducationAgededucation.field_of_studybusiness.industryCoronary StenosisStentPercutaneous coronary interventionTacrolimus eluting stent.Cardiovascular AgentsDrug-Eluting StentsGeneral MedicineMiddle Agedmedicine.diseaseTacrolimusSurgeryTreatment OutcomeAntiproliferative AgentsFemaleRadiologySafetyCardiology and Cardiovascular MedicinebusinessMaceCatheterization and cardiovascular interventions : official journal of the Society for Cardiac AngiographyInterventions
researchProduct